A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

September 5, 2017

Conditions
Advanced Multiple Myeloma
Interventions
DRUG

Filanesib, KSP (Eg5) inhibitor; intravenous

multiple dose, single schedule

DRUG

Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

standard of care

Trial Locations (60)

10029

Mount Sinai Medical Center, New York

10065

NY Presbyterian - Weill Cornell Medical Center, New York

20817

Center for Cancer and Blood Disorders, Bethesda

27710

Duke Cancer Center, Durham

28204

Levine Cancer Institute, Charlotte

29425

Medical University of South Carolina, Charleston

30322

Emory University, Winship Cancer Institute, Atlanta

35249

UAB Comprehensive Cancer Center, Birmingham

40202

Norton Cancer Institute, Louisville

40536

University of Kentucky, Lexington

44195

Cleveland Clinic, Cleveland

48201

Karmanos Cancer Institute, Detroit

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

62526

Decatur Memorial Hospital, Decatur

63130

Washington University in St. Louis, St Louis

66205

University of Kansas Cancer Center and Medical Pavilion, Westwood

68506

Nebraska Hematology Oncology, P.C., Lincoln

75390

UT Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

80218

Colorado Blood Cancer Institute, Denver

84112

Huntsman Cancer Institute, Salt Lake City

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

91010

City of Hope, Duarte

94143

University of California, San Francisco Medical Center, San Francisco

99216

Cancer Care Northwest, Spokane Valley

06510

Yale Comprehensive Cancer Center, New Haven

02111

Tufts Medical Center, Boston

Unknown

Institut Jules Bordet, Brussels

Universitaire Ziekenhuizen Leuven, Leuven

Tom Baker Cancer Centre, Calgary

QEII Health Sciences Center, Halifax

Jewish General Hospital, Montreal

Centre Hospitalier Lyon-Sud, Bierre-Benite Cedex

Hopital Claude Huriez, Lille

Institut Paoli Calmettes, Marseille

CHU Hotel Dieu, Nantes

G.H.U Caremeau, Nîmes

Institut Universitaire de Cancer, Toulouse

CHU tours-Hopital Bretonneau, Tours

CHU de Nancy - Hopital de Brabois, Vandœuvre-lès-Nancy

TU Dresden Medizinische Fakultat, Medizinische Klinik und Poliklinik I, Dresden

Asklepios Kliniken Hamburg GmbH, Hamburg

University Hospital Heidelberg, Heidelberg

University Hospital Leipzig, Leipzig

University of Tubingen, Tübingen

Julius Maximilians Universitat Wurzburg, Würzburg

"General Hospital of Athens Evangelismos", Athens

University of Athens School of Medicine, Athens

Hospital Germans Trias i Pujol, Badalona

Hospital Clinic de Barcelona, Barcelona

Hospital Clinico Universitario de Valencia, Valencia

Hospital Universitario La Fe, Valencia

Hospital Quiron de Zaragoza, Zaragoza

Barts Health NHS Trust, London

Kings College Hospital NHS Foundation Trust, London

Southhampton General Hospital, Southhampton

The Royal Marsden NHS Foundation Trust, Surrey

New Cross Hospital, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02092922 - A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | Biotech Hunter | Biotech Hunter